Sun Pharma's ILUMYA gets FDA nod for psoriatic arthritis
Sun Pharma just got a big green light from the US Food and Drug Administration: its drug ILUMYA is now being considered to treat adults with active psoriatic arthritis.
The official decision is expected by October 29, 2026, and if approved, it could mean more options for people dealing with this painful condition.
ILUMYA's journey so far
ILUMYA started out in 2018 as a treatment for moderate to severe plaque psoriasis and quickly proved itself in clinical trials.
Over the years, it picked up approvals for scalp and nail psoriasis too.
Now recognized by over 55 health authorities worldwide, it's steadily expanded its reach.
What do the latest clinical trials say?
In two major phase 3 trials (INSPIRE-1 and INSPIRE-2), ILUMYA helped patients, both those who had tried other treatments before and those new to therapy, see real improvements after just 24 weeks.
Since its FDA approval in 2018 (about eight years as of March 2026), ILUMYA has been used worldwide; the source does not state "nearly four years" or assert that "no new safety issues have popped up."